Autosomal dominant spastic paraplegia type 42
aw-toh-SOH-muhl doh-MI-nuhnt SPAS-tik par-uh-PLEE-jee-uh type 42
Also known as: SPG42, SLC33A1-related spastic paraplegia
At a Glance
What is Autosomal dominant spastic paraplegia type 42?
Autosomal dominant spastic paraplegia type 42 is a rare genetic disorder that primarily affects the nervous system. It is characterized by progressive weakness and stiffness of the leg muscles. This condition is caused by mutations in the SLC33A1 gene, which disrupts normal cellular function. Over time, individuals may experience worsening mobility and require assistance with walking. Early symptoms often include mild leg stiffness and difficulty with balance, while later symptoms can involve severe spasticity and muscle weakness. Early diagnosis is crucial to manage symptoms and improve quality of life. The disorder can have a significant impact on family life, as it may require long-term care and support. Prognosis varies, but many individuals maintain a normal life expectancy. Daily life for those affected may include physical therapy and the use of mobility aids. The condition can also lead to complications such as joint contractures and pain. Emotional and psychological support is important for both patients and their families. Genetic counseling is recommended for affected families to understand inheritance patterns and risks.
Medical Definition
Autosomal dominant spastic paraplegia type 42 is a hereditary neurodegenerative disorder caused by mutations in the SLC33A1 gene. Pathologically, it involves the degeneration of corticospinal tracts, leading to spasticity and weakness in the lower limbs. Histological findings typically show axonal degeneration and gliosis in affected neural pathways. It is classified under the hereditary spastic paraplegias, a group of disorders characterized by progressive spasticity and weakness. Epidemiologically, SPG42 is extremely rare, with a prevalence of approximately 1 in 1,000,000. The disease course is progressive, with symptoms worsening over time, often leading to significant physical disability.
Autosomal dominant spastic paraplegia type 42 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Lower limb spasticity manifests as increased muscle tone and stiffness in the legs, leading to difficulty in movement. This symptom is caused by disruptions in the central nervous system pathways that regulate muscle contraction, particularly affecting the corticospinal tract. Over time, spasticity can lead to muscle contractures and joint deformities if not managed properly. It affects daily life by limiting mobility and independence, but physical therapy and medications like baclofen can help manage the symptoms.
Progressive gait disturbance presents as an abnormal walking pattern, often characterized by a scissor-like movement of the legs. This occurs due to the combination of muscle weakness and spasticity, which disrupts normal coordination. As the condition progresses, walking becomes increasingly difficult, leading to a higher risk of falls and potential injury. Assistive devices such as canes or walkers, along with regular physiotherapy, can help maintain mobility and safety.
Muscle weakness primarily affects the lower limbs, making it difficult for individuals to perform tasks that require leg strength. It results from the degeneration of motor neurons that are responsible for muscle control. Over time, muscle weakness can lead to atrophy and further decrease in functional ability. Strengthening exercises and occupational therapy can support muscle function and improve quality of life.
Common
Urinary urgency is characterized by a sudden, strong need to urinate, often resulting in incontinence. This symptom arises due to spasticity affecting the detrusor muscle of the bladder. As the condition progresses, the frequency and severity of urinary urgency may increase, impacting daily activities and social interactions. Bladder training and medications such as anticholinergics can help manage this symptom.
Fatigue is a persistent feeling of tiredness and lack of energy that is not relieved by rest. It is thought to be caused by the increased effort required to perform daily activities due to muscle weakness and spasticity. Over time, fatigue can lead to decreased participation in social and occupational activities. Energy conservation techniques and lifestyle modifications can help manage fatigue levels.
Clonus is characterized by involuntary, rhythmic muscle contractions, often observed in the ankles. It occurs due to hyperexcitability of the stretch reflex arc in the affected muscles. Clonus can become more pronounced with disease progression, leading to discomfort and difficulty in maintaining balance. Physical therapy and medications like muscle relaxants can help reduce the frequency and severity of clonus.
Less Common
Dysarthria is a motor speech disorder resulting in slurred or slow speech that can be difficult to understand. It is caused by weakness or spasticity of the muscles used in speech production. Over time, dysarthria can affect communication, leading to social isolation. Speech therapy can improve articulation and communication skills.
Cognitive impairment may manifest as difficulties with memory, attention, and executive function. This symptom is thought to be related to the underlying neurological changes affecting the brain. As the condition progresses, cognitive challenges can impact daily functioning and quality of life. Cognitive rehabilitation and support strategies can help manage these difficulties.
What Causes Autosomal dominant spastic paraplegia type 42?
Autosomal dominant spastic paraplegia type 42 is caused by mutations in the SLC33A1 gene, located on chromosome 3q25.33. The SLC33A1 gene encodes the acetyl-CoA transporter protein, which is crucial for transporting acetyl-CoA into the lumen of the endoplasmic reticulum (ER). Mutations such as c.339T>G (p.Ser113Arg) alter the protein's structure, impairing its ability to transport acetyl-CoA. This disruption leads to an accumulation of acetyl-CoA in the cytosol and a deficit within the ER, affecting protein acetylation processes. The imbalance in acetylation disrupts ER function, leading to ER stress and impaired protein folding. Consequently, this stress triggers the unfolded protein response, which can lead to apoptosis if unresolved. Neighboring cells and tissues experience increased oxidative stress and inflammation due to the release of pro-inflammatory cytokines. Neuroinflammation exacerbates neuronal damage, contributing to the degeneration of white matter tracts in the spinal cord. The degeneration primarily affects the corticospinal tracts, leading to the characteristic spasticity and weakness in the lower limbs. Symptoms appear in a specific pattern due to the selective vulnerability of long motor neurons to ER stress and inflammation. Variability in disease severity among patients may be influenced by differences in genetic background, environmental factors, and the presence of modifying genes. Additionally, the age of onset and progression can vary, potentially due to differences in the efficiency of cellular stress response mechanisms. Understanding these molecular and cellular mechanisms provides insight into potential therapeutic targets for managing or treating the condition.
How is Autosomal dominant spastic paraplegia type 42 Diagnosed?
Typical age of diagnosis: Autosomal dominant spastic paraplegia type 42 is typically diagnosed in adulthood, often between the ages of 20 and 40, when patients begin to exhibit progressive lower limb spasticity and weakness. Diagnosis may occur earlier if there is a known family history of the condition, prompting earlier clinical evaluation. The condition is often suspected based on clinical presentation and family history, but confirmation requires genetic testing. Early diagnosis can help in managing symptoms and planning for long-term care.
The clinician looks for signs of progressive spasticity and weakness in the lower limbs, which are hallmark features of the condition. A detailed family history is crucial, as autosomal dominant inheritance suggests a genetic component. Physical examination typically reveals increased muscle tone, hyperreflexia, and gait disturbances. This step helps to differentiate spastic paraplegia from other neuromuscular disorders and guides further diagnostic testing.
Magnetic resonance imaging (MRI) of the brain and spinal cord is the imaging modality of choice. It may show corticospinal tract degeneration, which supports the diagnosis of spastic paraplegia. The imaging findings help confirm the diagnosis by excluding other structural causes of spasticity, such as multiple sclerosis or spinal cord lesions. MRI also assists in ruling out differential diagnoses like hereditary spastic paraplegia of other types.
Routine blood tests and cerebrospinal fluid analysis are typically normal and not specific for this condition. However, they are performed to exclude other causes of spasticity, such as metabolic or inflammatory disorders. Abnormal results in these tests would prompt consideration of alternative diagnoses. The lack of specific biomarkers for SPG42 means that laboratory tests mainly serve to support the exclusion of other conditions.
Genetic testing involves sequencing the SLC33A1 gene to identify pathogenic variants. Mutations such as c.339T>G (p.Ser113Arg) are commonly found in SPG42 patients. The presence of a pathogenic mutation confirms the diagnosis and allows for precise genetic counseling. Genetic results are crucial for informing family members about their risk and potential need for testing.
Autosomal dominant spastic paraplegia type 42 Treatment Options
Baclofen is a muscle relaxant that acts as a GABA-B receptor agonist to reduce spasticity. It is commonly used to alleviate muscle stiffness and improve mobility in patients with spastic paraplegia. Clinical evidence supports its efficacy in reducing spasticity, although it does not halt disease progression. Side effects may include drowsiness, weakness, and dizziness, which can limit its use in some patients. Dose adjustments and monitoring are necessary to optimize therapeutic effects while minimizing adverse effects.
Physical therapy focuses on gait training to improve walking ability and reduce spasticity. Techniques include stretching, strengthening exercises, and the use of assistive devices. Therapy sessions are typically conducted several times a week, with each session lasting about an hour. Measurable outcomes include improved gait speed and balance, contributing to enhanced quality of life. Long-term benefits include maintaining mobility and delaying the progression of disability.
Surgery is considered for severe spasticity that does not respond to conservative treatments. Selective dorsal rhizotomy involves cutting nerve roots in the spinal cord to reduce muscle tone. The procedure can significantly improve mobility and reduce pain, but it carries risks such as sensory loss or weakness. Post-operative care includes intensive rehabilitation to maximize functional gains. Surgical intervention is typically reserved for carefully selected patients with specific indications.
Supportive care involves a team of neurologists, physiotherapists, occupational therapists, and social workers. Interventions include mobility aids, home modifications, and vocational counseling. Psychosocial support strategies help patients and families cope with the emotional impact of the disease. Education focuses on disease management and the importance of adherence to therapy. Long-term monitoring ensures timely adjustments to the care plan as the condition progresses.
When to See a Doctor for Autosomal dominant spastic paraplegia type 42
- Sudden loss of mobility β this could indicate a severe progression or complication of the condition requiring immediate medical attention.
- Severe difficulty breathing β may suggest respiratory involvement which is a medical emergency.
- Loss of consciousness β could indicate a neurological crisis or other serious complication.
- Increasing difficulty walking β may indicate worsening of the condition and should prompt a medical review.
- Frequent falls β could suggest progression and may require intervention to prevent injury.
- New or worsening muscle weakness β significant as it may indicate disease progression and requires evaluation.
- Mild muscle stiffness β monitor for changes in severity or frequency.
- Occasional balance issues β keep track of any increase in frequency or severity.
Autosomal dominant spastic paraplegia type 42 β Frequently Asked Questions
Is this condition hereditary?
Autosomal dominant spastic paraplegia type 42 is inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to children. De novo mutations can occur, meaning the condition can appear in a child without a family history. Carrier status is not applicable as the condition is dominant. Genetic counseling is recommended for affected individuals and their families.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the age of onset and severity of symptoms. Early onset may lead to more significant disability, while later onset might have a milder course. Mortality is often related to complications such as falls or respiratory issues. Treatment can improve quality of life and manage symptoms, potentially extending survival. Realistic expectations include managing symptoms and maintaining mobility as much as possible.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months to years. Neurologists and geneticists are typically involved in the diagnostic process. Delayed diagnosis can occur due to symptom overlap with other conditions. Genetic testing confirms the diagnosis by identifying mutations in the SLC33A1 gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and other novel approaches being explored. Clinical trials can be found on ClinicalTrials.gov by searching for spastic paraplegia type 42. It is important to discuss potential participation in trials with your doctor. The timeline for new treatments becoming available can vary, often taking several years. Staying informed about research developments is crucial for accessing new therapies.
How does this condition affect daily life and activities?
The condition primarily impacts mobility, often requiring assistive devices for walking. Educational and occupational adaptations may be necessary to accommodate physical limitations. Social and emotional challenges include coping with disability and potential isolation. Family members may experience increased caregiving responsibilities. Supportive therapies and community resources can significantly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Identification and functional analysis of a SLC33A1: c.339T>G (p.Ser113Arg) variant in the original SPG42 family.
Mao F, Li Z, Zhao B et al. Β· Hum Mutat Β· 2015 Β· PMID: 25402622
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-30